CN104684932B - 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 - Google Patents

能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 Download PDF

Info

Publication number
CN104684932B
CN104684932B CN201380037161.1A CN201380037161A CN104684932B CN 104684932 B CN104684932 B CN 104684932B CN 201380037161 A CN201380037161 A CN 201380037161A CN 104684932 B CN104684932 B CN 104684932B
Authority
CN
China
Prior art keywords
antibody
blood
fxia
amino acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380037161.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN104684932A (zh
Inventor
A·威尔曼
J·斯特拉斯伯格
F·迪特默
M·施特雷拉特
A·布奇穆勒
J·格鲁德金斯卡-高宝
R·芬纳恩
M·沙弗尔
C·格德斯
H·乔里斯恩
亜沙子·板倉
P·外梁
E·塔克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CN104684932A publication Critical patent/CN104684932A/zh
Application granted granted Critical
Publication of CN104684932B publication Critical patent/CN104684932B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201380037161.1A 2012-05-10 2013-05-08 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途 Active CN104684932B (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP12167438.6 2012-05-10
EP12167438 2012-05-10
EP12181697 2012-08-24
EP12181697.9 2012-08-24
EP13150361 2013-01-07
EP13150361.7 2013-01-07
US201361817675P 2013-04-30 2013-04-30
US61/817,675 2013-04-30
PCT/EP2013/059618 WO2013167669A1 (en) 2012-05-10 2013-05-08 Antibodies capable of binding to the coagulation factor xi and/or its activated form factor xia and uses thereof

Publications (2)

Publication Number Publication Date
CN104684932A CN104684932A (zh) 2015-06-03
CN104684932B true CN104684932B (zh) 2019-03-12

Family

ID=49550177

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380037161.1A Active CN104684932B (zh) 2012-05-10 2013-05-08 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途

Country Status (24)

Country Link
US (4) US9783614B2 (enExample)
EP (2) EP2847228B1 (enExample)
JP (2) JP6348900B2 (enExample)
KR (1) KR102060376B1 (enExample)
CN (1) CN104684932B (enExample)
AR (1) AR091024A1 (enExample)
AU (2) AU2013258043B2 (enExample)
BR (1) BR112014027952B1 (enExample)
CA (1) CA2872926C (enExample)
DK (1) DK2847228T3 (enExample)
ES (1) ES2698950T3 (enExample)
HR (1) HRP20181680T1 (enExample)
HU (1) HUE040580T2 (enExample)
IL (1) IL235238B (enExample)
LT (1) LT2847228T (enExample)
MX (1) MX362454B (enExample)
NZ (1) NZ701121A (enExample)
PL (1) PL2847228T3 (enExample)
RS (1) RS57889B1 (enExample)
SG (2) SG11201406719UA (enExample)
SI (1) SI2847228T1 (enExample)
TW (2) TWI631140B (enExample)
WO (1) WO2013167669A1 (enExample)
ZA (1) ZA201407784B (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
HUE042940T2 (hu) 2008-12-18 2019-07-29 Univ Oregon Health & Science Anti-FXI antitestek és alkalmazási eljárások
IN2014CN02806A (enExample) 2011-10-14 2015-07-03 Bristol Myers Squibb Co
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
PL2766346T3 (pl) 2011-10-14 2017-09-29 Bristol-Myers Squibb Company Podstawione związki tetrahydroizochinoliny jako inhibitory czynnika XIA
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe
EP2906541B1 (en) 2012-10-12 2017-11-22 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EA032092B1 (ru) 2012-10-12 2019-04-30 Бристол-Майерс Сквибб Компани Кристаллические формы ингибитора фактора xia
JP6479763B2 (ja) 2013-03-25 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ｘｉａ因子阻害剤としての置換アゾール含有のテトラヒドロイソキノリン
ES2687498T3 (es) 2014-01-31 2018-10-25 Bristol-Myers Squibb Company Macrociclos con grupos P2¿ heterocíclicos como inhibidores del factor XIa
NO2760821T3 (enExample) 2014-01-31 2018-03-10
WO2016020882A2 (en) 2014-08-07 2016-02-11 Novartis Ag Angiopoetin-like 4 (angptl4) antibodies and methods of use
MA40512A (fr) 2014-08-07 2021-03-24 Novartis Ag Anticorps de l'angiopoïétine-like 4 et procédés d'utilisation correspondants
ES2714283T3 (es) 2014-09-04 2019-05-28 Bristol Myers Squibb Co Macrociclos de diamida que son inhibidores de FXIa
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
CA2972800A1 (en) 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
JOP20200312A1 (ar) * 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
US10913802B2 (en) 2015-07-21 2021-02-09 Dyax Corp. Monoclonal antibody inhibitor of factor XIIA
US11066481B2 (en) 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
MA43660A (fr) 2016-01-22 2018-11-28 Adimab Llc Anticorps anti-facteur xi de coagulation
CA3018124A1 (en) * 2016-03-23 2017-09-28 Prothix Bv Monoclonal antibodies against the active site of factor xi and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
TWI752964B (zh) 2016-06-14 2022-01-21 美商默沙東藥廠 抗凝血因子ｘｉ抗體
PE20191319A1 (es) 2016-09-20 2019-09-24 Bayer Pharma AG Anticuerpos novedosos contra el factor xi y sus usos
EP3535390A4 (en) * 2016-11-02 2020-11-25 Inc. Aronora COMBINATION OF THROMBIN E-WE ANALOGUE AND FIBRINOLYTIC
IL308980A (en) * 2016-12-23 2024-01-01 Novartis Ag Antibodies against factor XI and methods of their use
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
PT3570882T (pt) 2017-01-19 2022-01-11 Bayer Pharma AG Nova formulação estável para anticorpos fxia
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US11958911B2 (en) * 2017-02-10 2024-04-16 Shanghai Benemae Pharmaceutical Anti-coagulation factor XI antibody
CN111902427A (zh) * 2017-11-22 2020-11-06 诺华股份有限公司 抗因子XI/XIa抗体的逆转结合剂及其用途
BR112020026492A2 (pt) * 2018-07-05 2021-04-06 Bayer Aktiengesellschaft Método para a produção de péletes liofilizados compreendendo um anticorpo antifator de coagulação xia (fxia)
MY202203A (en) * 2018-08-01 2024-04-17 Novo Nordisk As Improved procoagulant antibodies
EP4246834B1 (en) 2018-08-07 2025-01-01 Nippon Telegraph And Telephone Corporation Optical transport system
CN116554334A (zh) * 2018-08-09 2023-08-08 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
US20220016162A1 (en) * 2018-09-17 2022-01-20 Board Of Regents, The University Of Texas System Compositions and methods for treating bone injury
US20210395390A1 (en) 2018-10-31 2021-12-23 Bayer Aktiengesellschaft Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
CN113474373B (zh) * 2019-01-21 2025-09-02 阿罗诺拉股份有限公司 具有抗血栓形成和抗炎作用的新型抗因子xi人源化抗体及其用途
KR20210151774A (ko) 2019-04-16 2021-12-14 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-FXI/FXIa 항체 및 그 용도
CN110423278B (zh) * 2019-08-08 2020-07-17 上海博槿生物科技有限公司 一种抗凝血因子XI活化形式因子XIa的抗体及其制备方法和应用
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
MX2022015959A (es) * 2020-07-02 2023-01-24 Beijing Tuo Jie Biopharmaceutical Co Ltd Anticuerpo anti-fxi/fxia, fragmento de union a antigeno del mismo y uso farmaceutico del mismo.
EP4644426A1 (en) * 2022-12-30 2025-11-05 Gan & Lee Pharmaceuticals Co., Ltd. Antibody against coagulation factor xi and/or activated form factor xia thereof, and use thereof
CN119454938B (zh) * 2024-11-15 2025-07-25 广州骐骥生物科技有限公司 一种枸橼酸透析浓缩液及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
CA2747519A1 (en) * 2008-12-18 2010-07-15 Oregon Health & Science University Anti-fxi antibodies and methods of use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
DE4319041A1 (de) 1992-10-23 1994-04-28 Bayer Ag Trisubstituierte Biphenyle
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
US20030235587A1 (en) 1998-08-07 2003-12-25 Feuerstein Giora Z. Anticoagulant agents useful in treatment of thrombosis
JP4351298B2 (ja) 1996-10-14 2009-10-28 バイエル・アクチエンゲゼルシヤフト 新規へテロシクリルメチル置換ピラゾール誘導体
DE19642255A1 (de) 1996-10-14 1998-04-16 Bayer Ag Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten
DE19649460A1 (de) 1996-11-26 1998-05-28 Bayer Ag Neue substituierte Pyrazolderivate
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834045A1 (de) 1998-07-29 2000-02-03 Bayer Ag (4-Amino-5-ethylpyrimidin-2-yl)-1-(2-fluorbenzyl)-1H-pyrazolo[3,4-b]pyridin
WO2000007626A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
DE19846514A1 (de) 1998-10-09 2000-04-20 Bayer Ag Neue Heterocyclyl-methyl-substituierte Pyrazole
DE19920352A1 (de) 1999-05-04 2000-11-09 Bayer Ag Substituiertes Pyrazolderivat
DE19942809A1 (de) 1999-09-08 2001-03-15 Bayer Ag Verfahren zur Herstellung substituierter Pyrimidinderivate
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
WO2003013423A2 (en) 2001-08-05 2003-02-20 Gvg, Inc. Antithrombotic agent
US20080138837A1 (en) 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
US7279513B2 (en) 2004-11-19 2007-10-09 Nalco Company Preparation of neutralized ethylene-acrylic acid polymer dispersions and use in printing media for improvement of digital toner adhesion
DE102005050497A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Difluorphenol-Derivate und ihre Verwendung
DE102005050498A1 (de) 2005-10-21 2007-06-06 Bayer Healthcare Aktiengesellschaft Cyclopropylessigsäure-Derivate und ihre Verwendung
DE102005050377A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Heterocyclische Verbindungen und ihre Verwendung
DE102005050375A1 (de) 2005-10-21 2007-04-26 Bayer Healthcare Ag Tetrazol-Derivate und ihre Verwendung
DE102005050376A1 (de) 2005-10-21 2007-05-31 Bayer Healthcare Ag Dicarbonsäure-Derivate und ihre Verwendung
PL2059535T3 (pl) 2006-08-18 2014-04-30 Novartis Ag Przeciwciało specyficzne względem PRLR i jego zastosowanie
JP2010526066A (ja) 2007-04-23 2010-07-29 シェーリング コーポレイション 抗ｍｄｌ−１抗体
US8574849B2 (en) 2007-10-03 2013-11-05 The University Of Vermont And State Agriculture College Methods of detection of factor XIa and tissue factor
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
EP2373317B1 (en) 2008-11-25 2016-12-14 Merck Sharp & Dohme Corp. 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
CA2800541C (en) 2010-05-27 2016-03-22 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
EP2585055A1 (de) 2010-06-25 2013-05-01 Bayer Intellectual Property GmbH Verwendung von stimulatoren und aktivatoren der löslichen guanylatzyklase zur behandlung von sichelzellanämie und konservierung von blutersatzstoffen
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
WO2012143510A1 (de) 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Fluoralkyl-substituierte pyrazolopyridine und ihre verwendung
CN103649093B (zh) 2011-05-06 2017-07-07 拜耳知识产权有限责任公司 取代的咪唑并吡啶和咪唑并哒嗪及其用途
EP2763990B1 (en) 2011-09-01 2017-02-22 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
WO2013030288A1 (de) 2011-09-02 2013-03-07 Bayer Intellectual Property Gmbh Substituierte annellierte pyrimidine und ihre verwendung
SI2847228T1 (sl) * 2012-05-10 2018-11-30 Bayer Pharma Aktiengesellschaft Protitelesa zmožna vezave na faktor koagulacije XI in/ali njeno aktivirano obliko faktor XIa in njihove uporabe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009154461A1 (en) * 2008-06-19 2009-12-23 Prothix Bv Use of anti-factors xi antibodies for prevention of thrombus formation
CA2747519A1 (en) * 2008-12-18 2010-07-15 Oregon Health & Science University Anti-fxi antibodies and methods of use

Also Published As

Publication number Publication date
US10221247B2 (en) 2019-03-05
TWI644925B (zh) 2018-12-21
US10040866B2 (en) 2018-08-07
US20190284300A1 (en) 2019-09-19
BR112014027952A2 (pt) 2019-07-09
WO2013167669A1 (en) 2013-11-14
BR112014027952B1 (pt) 2022-06-21
US9783614B2 (en) 2017-10-10
AU2013258043B2 (en) 2017-11-30
SG10201609322QA (en) 2017-01-27
DK2847228T3 (en) 2018-11-19
PL2847228T3 (pl) 2019-03-29
JP2015517305A (ja) 2015-06-22
CA2872926A1 (en) 2013-11-14
ES2698950T3 (es) 2019-02-06
JP2018148920A (ja) 2018-09-27
CA2872926C (en) 2022-07-05
US20150099298A1 (en) 2015-04-09
LT2847228T (lt) 2018-11-12
AU2018200850C1 (en) 2020-03-12
CN104684932A (zh) 2015-06-03
ZA201407784B (en) 2019-01-30
AU2018200850B2 (en) 2019-09-19
KR20150008166A (ko) 2015-01-21
MX362454B (es) 2019-01-18
EP2847228A1 (en) 2015-03-18
MX2014013568A (es) 2014-12-08
AU2013258043A1 (en) 2014-11-13
HK1207091A1 (en) 2016-01-22
HUE040580T2 (hu) 2019-03-28
US20180051093A1 (en) 2018-02-22
IL235238A0 (en) 2014-12-31
SG11201406719UA (en) 2014-11-27
RS57889B1 (sr) 2019-01-31
TWI631140B (zh) 2018-08-01
IL235238B (en) 2019-08-29
EP2847228B1 (en) 2018-07-25
US11046783B2 (en) 2021-06-29
SI2847228T1 (sl) 2018-11-30
HRP20181680T1 (hr) 2018-12-14
EP3404045A1 (en) 2018-11-21
TW201400504A (zh) 2014-01-01
AR091024A1 (es) 2014-12-30
JP6348900B2 (ja) 2018-06-27
KR102060376B1 (ko) 2019-12-30
US20180112009A1 (en) 2018-04-26
AU2018200850A1 (en) 2018-02-22
NZ701121A (en) 2017-06-30
TW201811834A (zh) 2018-04-01

Similar Documents

Publication Publication Date Title
CN104684932B (zh) 能够结合凝血因子XI和/或其活化形式因子XIa的抗体及其用途
JP6843816B2 (ja) Ｐｄｇｆ受容体ベータ結合ポリペプチド
JP6669800B2 (ja) Ｍａｓｐ−２依存性の補体活性化を阻害するための組成物
CN114316061B (zh) 针对血浆激肽释放酶和因子xii的双特异性抗体
JP5801194B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
EA036490B1 (ru) Антитела, связывающиеся с tfpi, и содержащая их композиция
JP6559188B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP6848016B2 (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
JP2018038398A (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体
TR201815476T4 (tr) Koagülasyon Faktörü XI ve/veya bunun aktive formu faktör XIa'ya bağlanabilen antikorlar ve bunların kullanımları.
HK1207091B (zh) 能够结合凝血因子xi和/或其活化形式因子xia的抗体及其用途
JP2021091720A (ja) 組織因子経路インヒビター（ｔｆｐｉ）に対するモノクローナル抗体

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1207091

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant